Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J McConkey

Showing results (21-30 of 203) with videos related to

Pageof 21
Sort By:
Advances in Cancer Research|October 24, 2012
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancerDavid J McConkey, Matthew White, Wudan Yan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma linesYasmine Haddad, Woonyoung Choi, David J McConkey
Anticancer Research|August 10, 2002
Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomasTomoyuki Agui, David J McConkey, Nobuhiko Tanigawa
Current Opinion in Urology|July 29, 2015
Genetic subtypes of invasive bladder cancerDavid J McConkey, Woonyoung Choi, Colin P N Dinney
European Urology|June 1, 2014
New insights into subtypes of invasive bladder cancer: considerations of the clinicianDavid J McConkey, Woonyoung Choi, Colin P N Dinney
Cancer Biology & Therapy|July 10, 2007
Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cellsAngela Papageorgiou, Colin P N Dinney, David J McConkey
Current Opinion in Urology|August 10, 2004
Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE)Ralph A Highshaw, David J McConkey, Colin P Dinney
Current Oncology Reports|October 17, 2015
Targeting Signaling Transduction Pathways in Bladder CancerPhillip H Abbosh, David J McConkey, Elizabeth R Plimack
Nature Reviews. Clinical Oncology|May 19, 2011
Autophagy as a target for anticancer therapyFilip Janku, David J McConkey, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
New strategies in muscle-invasive bladder cancer: on the road to personalized medicineJay B Shah, David J McConkey, Colin P N Dinney
Pageof 21

Showing results (21-30 of 203) with videos related to

Sort By:
Pageof 21
Advances in Cancer Research|October 24, 2012
HDAC inhibitor modulation of proteotoxicity as a therapeutic approach in cancerDavid J McConkey, Matthew White, Wudan Yan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2009
Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma linesYasmine Haddad, Woonyoung Choi, David J McConkey
Anticancer Research|August 10, 2002
Comparative study of various biological parameters, including expression of survivin, between primary and metastatic human colonic adenocarcinomasTomoyuki Agui, David J McConkey, Nobuhiko Tanigawa
Current Opinion in Urology|July 29, 2015
Genetic subtypes of invasive bladder cancerDavid J McConkey, Woonyoung Choi, Colin P N Dinney
European Urology|June 1, 2014
New insights into subtypes of invasive bladder cancer: considerations of the clinicianDavid J McConkey, Woonyoung Choi, Colin P N Dinney
Cancer Biology & Therapy|July 10, 2007
Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cellsAngela Papageorgiou, Colin P N Dinney, David J McConkey
Current Opinion in Urology|August 10, 2004
Integrating basic science and clinical research in bladder cancer: update from the first bladder Specialized Program of Research Excellence (SPORE)Ralph A Highshaw, David J McConkey, Colin P Dinney
Current Oncology Reports|October 17, 2015
Targeting Signaling Transduction Pathways in Bladder CancerPhillip H Abbosh, David J McConkey, Elizabeth R Plimack
Nature Reviews. Clinical Oncology|May 19, 2011
Autophagy as a target for anticancer therapyFilip Janku, David J McConkey, David S Hong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2011
New strategies in muscle-invasive bladder cancer: on the road to personalized medicineJay B Shah, David J McConkey, Colin P N Dinney
Pageof 21